Two attacks on Qatari entities signal a shift in focus for China-backed actors and demonstrate how quickly they can pivot in response to geopolitical events.
Eli Lilly CEO David Ricks seeks ‘exit velocity’ for pharma’s future
Can Eli Lilly escape the boom-and-bust cycle that has long defined the pharma business? In January, Lilly CEO David Ricks was on stage with Nvidia CEO Jensen Huang. Ricks had recently (if briefly) joined the …
NHS cleared to use Astellas’ non-hormonal menopause drug
Around half a million women will soon be able to access Astellas’ Veoza treatment for symptoms like hot flushes associated with menopause.
Integrating remote blood pressure monitoring into NHS primary care: a human factors perspective
BackgroundHypertension remains a major health burden in the UK, contributing significantly to cardiovascular disease and health inequalities. Although digital health technologies offer opportunities to enhance hypertension management, current NHS pathways face challenges, including inefficiencies in patient monitoring, limited patient engagement, and resource constraints. This study aimed to evaluate integration challenges of remote digital monitoring tools […]
Hustlers are cashing in on China’s OpenClaw AI craze
Feng Qingyang had always hoped to launch his own company, but he never thought this would be how—or that the day would come this fast. Feng, a 27-year-old software engineer based in Beijing, started tinkering with OpenClaw, a popular new open-source AI tool that can take over a device and autonomously complete tasks for a […]
AstraZeneca recruits Joshua Jackson, Philadelphia Flyers’ Gritty to cancer screening push
As AstraZeneca kicks off the third year of its hockey-themed “Get Body Checked Against Cancer” campaign, the pharma has tapped two celebs known for their work both on and off the ice.
Vertex preps FDA filing for IgAN drug after phase 3 readout
Vertex’s bid to expand beyond cystic fibrosis has taken a big step forward with phase 3 data for povetacicept in severe kidney disorder IgAN.
Veeva shells out $100M for Ostro and its AI chat tool for pharma brand engagement
Veeva Systems, which offers life sciences companies cloud-based commercial management software and business consulting services, is venturing into the consumer-facing side of things with the acquisition of Ostro.
Three Misconceptions that Limit Point of Care Marketing Impact
Point-of-care marketing promises conversion, but many strategies miss the prescribing moment. Are these common assumptions undermining your results?
NICE says no to Genmab cervical cancer therapy
Genmab’s recently approved therapy for relapsed cervical cancer has been turned down for NHS use in initial NICE guidance.
RA Capital, Forbion and Canaan appear to back Harbour’s CTLA-4 partner Solstice
For the second month in a row, it appears Forbion and RA Capital are the main backers behind a new biotech formed around an investigational drug in-licensed from China. Solstice Oncology was forced out of …
Veeva buys brand engagement firm Ostro for $100m
Veeva Systems has reached a $100m deal to acquire Ostro, which helps pharma connect with doctors and patients using AI-based conversational tools.